| Autor: |
Funke A; Universidade Federal do Paraná (UFPR), Hospital de Clínicas, Serviço de Reumatologia, Curitiba, PR, Brasil., Staub HL; Pontifícia Universidade Católica do Rio Grande do Sul (PUC-RS), Escola de Medicina, Serviço de Reumatologia, Porto Alegre, RS, Brasil., Monticielo OA; Universidade Federal do Rio Grande do Sul (UFRGS), Departamento de Medicina Interna, Hospital de Clínicas de Porto Alegre (HCPA), Serviço de Reumatologia, Porto Alegre, RS, Brasil., Balbi GGM; Universidade Federal de Juiz de Fora (UFJF), Hospital Universitário, Serviço de Reumatologia, Juiz de Fora, MG, Brasil., Danowski A; Hospital Federal dos Servidores do Estado (HFSE), Serviço de Reumatologia, Rio de Janeiro, RJ, Brasil., Santiago MB; Universidade Federal da Bahia (Hupes) e Escola Baiana de Medicina e Saúde Pública, Salvador, BA, Brasil., Andrade DCO; Universidade de São Paulo (USP), Divisão de Reumatologia, São Paulo, SP, Brasil., Rêgo J; Universidade Federal de Goiás (UFG), Faculdade de Medicina, Serviço de Reumatologia, Goiânia, GO, Brasil. |
| Abstrakt: |
The 2006 Revised Sapporo Classification Criteria for Definite Antiphospholipid Syndrome included as laboratory criteria the tests for antiphospholipid antibodies whose accuracy was regarded as satisfactory according to the evidence available at that time. In practice, however, the sensitivity and specificity of these "criteria" of antiphospholipid antibodies are sometimes insufficient for identifying or ruling out antiphospholipid syndrome. It has been studied whether the accuracy of the laboratory diagnosis of the syndrome could be improved by testing for non-criteria antiphospholipid antibodies. In this work, we review evidence on the clinical associations and diagnostic value of the most commonly studied non-criteria antibodies, namely: antiphosphatidylethanolamine, anti-annexin A5, anti-prothrombin, anti-phosphatidylserine/prothrombin complex, IgA anticardiolipin, and IgG anti-domain I of the β2 glycoprotein antibodies. |
